Madam Chair, I completely agree with Dr. Haggie's comments. I would say it's important that the committee recognize the temporal difference between peer-reviewed literature--expert use of drugs, which emerges very quickly--and regulatory response. There will be a gap at times.
I think the committee ought to use the term “inappropriate” off-label prescribing as its major interest as opposed to just off-label prescribing, because there certainly is appropriate off-label prescribing as well.